{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:32:05Z","timestamp":1786739525761,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>HCQ gained importance following the National Task Force advisory as an anti-SARS-Cov-2 (coronavirus disease-2019 [COVID-19]) drug for frontline healthcare workers (including anesthesiologists). Report of a young anesthesiologist in Assam developing cardiac arrest following HCQ intake for COVID-19 prophylaxis made us even more concerned. A conscious decision has been made by a large majority among us\u2013\u2013to have or not to have HCQ. However, less severe complications such as gastrointestinal upset, skin-rash, visual-disturbance, headache, and dizziness even if experienced by HCQ users were likely to go unreported unless shared. The present survey was conducted to assess the prevailing perception among Indian anesthesiologists about HCQ's preventive effect against COVID-19. The information has been pooled together and discussed in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>A total of 247 respondents participated in this pan-India survey. The survey questionnaire was prepared using \u201cGoogle Forms\u201d and conducted via links delivered through WhatsApp and electronic-mail.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>55.9% (138\/247) of the respondents had consumed HCQ, 38% (94\/247) did not, and 6.1% (15\/247) were undecided at the time of responding to the survey. In total, 47 respondents who ingested HCQ reported a side-effect, gastritis being the commonest (31).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The evidence for the effectiveness of HCQ against COVID-19 in India is reportedly as strong and weak as other drugs that have been promoted. The survey highlights the reasons consumption of HCQ and represents the opinion of 247 practicing Indian anesthesiologists. It informs the benefits and side effects of HCQ, which can help others in reaching a balanced decision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joacp.joacp_379_20","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T11:23:54Z","timestamp":1604575434000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The COVID-19 hydroxychloroquine prophylaxis perception of Indian anesthesiologists"],"prefix":"10.4103","volume":"36","author":[{"given":"Shagun B.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Pahade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-8-20260203","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4103\/jfmpc.jfmpc_728_20","article-title":"Preventive and treatment strategies of COVID-19: From community to clinical trials","volume":"9","author":"Sahu","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"R4-8-20260203","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"R6-8-20260203","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R7-8-20260203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"R9-8-20260203","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.oooo.2020.03.047","article-title":"Hydroxychloroquine and \u201coff-label\u201d utilization in the treatment of oral conditions","volume":"129","author":"Brown","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R15-8-20260203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.dsx.2020.03.012","article-title":"Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)","volume":"14","author":"Gupta","year":"2020","journal-title":"Diabetes Metabo Syndr"},{"key":"R16-8-20260203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"R19-8-20260203","first-page":"e1000013","article-title":"Corona virus drugs\u2013a brief overview of past, present and future","volume":"2","author":"Basha","year":"2020","journal-title":"J Peer Scientist"},{"key":"R20-8-20260203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbi.2020.04.046","article-title":"Current status of potential therapeutic candidates for the COVID-19 crisis","volume":"87","author":"Zhang","year":"2020","journal-title":"Brain Behav Immun"}],"container-title":["Journal of Anaesthesiology Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joacp.JOACP_379_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:41Z","timestamp":1786735781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joacp.JOACP_379_20"}},"subtitle":["A survey-based original article"],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/joacp.joacp_379_20","relation":{},"ISSN":["0970-9185"],"issn-type":[{"value":"0970-9185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}